Indiana University

Kovina Therapeutics, Inc.

University of Colorado

University of Virginia Patent Foundation

Other

The United States Government As Represented by the Department of Veterans Affairs

Samy O Meroueh

David B Ross

Elliot J Androphy

Michael Fitzpatrick Wempe

Dan Theodorescu

Phillip Reigan

Martin A Schwartz

Zhijian Lu

David T Ross

Anne Rietz

Fletcher A White

Alexander G Obukhov

David Ross

This invention relates to pyrazolylacylpyrazoline compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat neurological disorders.

Pyrazolylacylpyrazoline compounds and method for treating pain

The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.

Anti-cancer compounds targeting Ral GTPases and methods of using the same

The invention provides compositions, compounds, formulations, and methods for treating HPV infections including pre-malignant infections and cancer. Compounds that covalently bind to the HPV E6 protein are disclosed.

Compositions and methods for treating human papilloma virus infections

Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.

Small molecule antiviral drug treatment for human papillomavirus infections

Anti-cancer compounds targeting ral GTPases and methods of using the same

Compounds and methods for treating or preventing cancer associated with binding to the urokinase receptor are provided. Biological processes affected by the compounds include cell migration, cell growth, cell adhesion, angiogenesis, cancer cell invasion, apoptosis, tumor formation, tumor progression, metastasis, degradation of the extracellular matrix, pericellular proteolysis, activation of plasminogen, changes in the levels of an extracellular protease, and changes in the levels of a VEGF receptor.

Compounds and methods for treating cancer by inhibiting the urokinase receptor

The invention described herein pertains to compounds, compositions and formulations comprising the compounds, and methods for use of the compounds, compositions and/or formulations in the treatment of diseases responsive to the inhibition of uPAR-uPA interactions, such as cancer.

uPAR-uPA interaction inhibitors and methods for treating cancer

Growing community of inventors

Carmel, IN, United States of America

Samy O Meroueh